First Course of treatment and Prognosis of Exocrine Pancreatic Cancer in Korea from 2006 to 2017
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Purpose: Hospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea. Materials and methods: The Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to the Surveillance, Epidemiology, and End Results (SEER) program. Results: Among 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. "No active treatment" (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017. Conclusion: Less than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice.
Abstract
Purpose: Hospital-based clinical studies have limitations in holistic assessment of cancer treatment and prognosis, as they omit out-of-hospital patients including elderly individuals. This study aimed to investigate trends in initial treatment and corresponding prognosis of patients with exocrine pancreatic cancer (EPC) in Korea. Materials and methods: The Korea Central Cancer Registry data of patients with EPC from 2006 to 2017 were retrospectively reviewed. We defined the first course of treatment (FT) as the cancer-directed treatment administered within four months after cancer diagnosis according to the Surveillance, Epidemiology, and End Results (SEER) program. Results: Among 62,209 patients with EPC, localized and regional (LR) SEER stage; patients over 70 years old; and ductal adenocarcinoma excluding cystic or mucinous (DAC) accounted for 40.6%, 50.1%, and 95.9%, respectively. "No active treatment" (NT, 46.5%) was the most frequent, followed by non-surgical FT (28.7%) and surgical FT (22.0%). Among 25,198 patients with LR EPC, surgical FT increased (35.9% to 46.3%) and NT decreased (45.0% to 29.5%) from 2006 to 2017. The rate of surgical FT was inversely related to age (55.1% [< 70 years], 37.3% [70-79 years], 10.9% [≥ 80 years]). Five-year relative survival rates of LR DAC were higher after surgical FT than after NT in localized (46.1% vs. 12.9%) and regional stage (23.6% vs. 4.9%) from 2012 to 2017. Conclusion: Less than half of overall patients with LR EPC underwent surgical FT, and this proportion decreased significantly in elderly individuals. Clinicians should focus attention on elderly patients with EPC to provide appropriate medical advice.
참고문헌 (30)
- "Cancer today; pancreas (C25)" (2020)[URL]
- "NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, version 2.2021" (2021)[URL]
- Khorana AA, "Potentially curable pancreatic adenocarcinoma : ASCO clinical practice guideline update", J Clin Oncol, 37, pp.2082~2088 (2019)
- Ducreux M, "Cancer of the pancreas : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v56~v68 (2015)
- LutfiW, "Health disparities impact expected treatment of pancreatic ductal adenocarcinoma nationally", Ann Surg Oncol, 25, pp.1860~1867 (2018)
- Huang L, "Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014 : a large international population-based study", Int J Cancer, 143, pp.3227~3239 (2018)
- "Indicators: life expectancy at birth, total (years)" (2021)[URL]
- "Surveillance, Epidemiology, and End Results Program. Cancer stat facts: pancreatic cancer" (2020)[URL]
- Dimou F, "Trends in receipt and timing of multimodality therapy in early-stage pancreatic cancer", J Gastrointest Surg, 20, pp.93~103 (2016)
- Hue JJ, "Mortality and survival among octogenarians with localized pancreatic head xancer : a national cancer database analysis", J Gastrointest Surg, 25, pp.2582~2592 (2021)
- Kang MJ, "Impact of changes in the topographic classification of Klatskin tumor on incidence of intra-and extrahepatic bile duct cancer : a population-based national cancer registry study", J Hepatobiliary Pancreat Sci, 28, pp.740~750 (2021)
- "SEER training modules" (2020)[URL]
- Rawla P, "Epidemiology of pancreatic cancer : global trends, etiology and risk factors", World J Oncol, 10, pp.10~27 (2019)
- World Health Organization, "ICD-10: international statistical classification of diseases and related health problems. 10th revision, version for 2010" (2010), World Health Organization
- Man D, "Prognosis of patients with neuroendocrine tumor : a SEER database analysis", Cancer Manag Res, 10, pp.5629~5638 (2018)
- Gordon-Dseagu VL, "Pancreatic cancer incidence trends : evidence from the Surveillance, Epidemiology and End Results(SEER)population-based data", Int J Epidemiol, 47, pp.427~439 (2018)
- "Standards for oncology registry entry (STORE) 2018" (2021)[URL]
- Ederer F, "Instructions to IBM 650 programmers in processing survival computations. Vol. 10" (1959), National Cancer Institute
- "Barriers to early cancer diagnosis and treatment" (2019)[URL]
- Kasumova GG, "Regional variation in the treatment of pancreatic adenocarcinoma : decreasing disparities with multimodality therapy", Surgery, 162, pp.275~284 (2017)
- Abdel-Rahman O, "A real-world, population-based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer", Cancer Med, 7, pp.6385~6392 (2018)
- Mavros MN, "Low rates of specialized cancer consultation and cancer-directed therapy for noncurable pancreatic adenocarcinoma : a population-based analysis", CMAJ, 191, pp.E574~E580 (2019)
- Shin Y, "The health insurance system in Korea and its implications", World Hosp Health Serv, 31, pp.3~9 (1995)
- 엄방울, "Trends and Outcomes of Non-compliance with Treatment for Gastric Cancer in Korea over the 16 years from 1999 to 2015", Journal of Gastric Cancer, 19(1), pp.92~101 (2019), 대한위암학회[DOI]
- Bilimoria KY, "National failure to operate on early stage pancreatic cancer", Ann Surg, 246, pp.173~180 (2007)
- Kirkegard J, "Waiting time to surgery and pancreatic cancer survival : a nationwide population-based cohort study", Eur J Surg Oncol, 45, pp.1901~1905 (2019)
- van der Geest LG, "Pancreatic cancer surgery in elderly patients: balancing between short-term harm and long-term benefit. A population-based study in the Netherlands", Acta Oncol, 55, pp.278~285 (2016)
- Suzuki T, "Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan", Jpn J Clin Oncol, 51, pp.228~234 (2021)
- King JC, "Deviations from expected treatment of pancreatic cancer in octogenarians : analysis of patient and surgeon factors", Ann Surg Oncol, 23, pp.4149~4155 (2016)
- Marosi C, "Challenge of cancer in the elderly", ESMO Open, 1, pp.e000020~ (2016)